Risk for DVT and PE as a complication of treatment with ADT

A newly published paper in Prostate Cancer and Prostatic Diseases has confirmed that there is an association between specific forms of androgen deprivation therapy (ADT) and certain types of adverse thromboembolic events. … READ MORE …

Metformin + ADT in treatment of advanced prostate cancer

Yet another study, just published in the Journal of Urology, has indicated a clear association between the use of metformin along with androgen deprivation therapy (ADT) in the treatment of advanced forms of prostate cancer. … READ MORE …

Adjuvant mitoxantrone + prednisone + ADT in treatment of high-risk prostate cancer

About 25 years ago the addition of the combination of mitoxantrone + prednisone to androgen deprivation therapy (ADT) was the first form of chemotherapy ever approved for the treatment of metastatic, castration-resistant prostate cancer. … READ MORE …

Let’s prove the obvious all over again

Once again your sitemaster finds himself flabbergasted at just how often we need to repeat similar experiments to prove the obvious. … READ MORE …

Mental health and ADT: an objective review

As regular readers will be aware, there has been some intense debate over the past year or so about whether there is an association between treatment with androgen deprivation therapy (ADT) and risk for dementia. … READ MORE …

Low PSA levels on ADT do correlate to longer survival times

For many years now, people have asked whether specific PSA levels after initiation of androgen deprivation therapy (ADT, also known as “hormone therapy”)  have significant predictive impact on long-term survival. … READ MORE …

When can ADT be safely avoided with salvage radiation therapy?

Two randomized clinical trials (GETUG-AFU-16 and RTOG 9601) proved that adding at least some ADT to salvage radiation (SRT) improved outcomes. “Some ADT” was 6 months of goserelin acetate in the GETUG-AFU-16 trial, and 2 years of bicalutamide in the RTOG 9601 trial. … READ MORE …